Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide

Lee, Fa-Chyi; Merchant, Shakil H.

doi:10.1002/ajh.10310

Cited by 47 publications

(38 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This remission was not sustained and recurrence was observed (46). Recent case reports of treatment with thalidomide also showed resolution of systemic manifestations of MCD (47,48). Thalidomide is known to have a powerful anti-cytokine effect and inhibits tumour necrosis factor and other proinflammatory cytokines.…”

Section: Therapymentioning

confidence: 90%

Fifty years of multicentric Castleman's disease

2004

View full text Add to dashboard Cite

Section: Therapymentioning

confidence: 90%

Fifty years of multicentric Castleman's disease

2004

View full text Add to dashboard Cite

“…There is one case report of employing thalidomide as a therapy for multicentric CD in an HIV-negative patient [49]. The authors treated a woman of 37 years of age who presented with anemia, thrombocytopenia, ascites, multicentric lymphadenopathy, pleural effusions, and severe tricuspid regurgitation.…”

Section: Thalidomidementioning

confidence: 98%

Treatment of castleman’s disease

Dispenzieri

Gertz

2005

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Castleman's disease (CD) was first described in 1954 and further defined in 1956 by Castleman. Since then much has been learned about the heterogeneity of this condition. Subsequently, three pathologic classifications have been developed (hyaline vascular variant, plasma cell variant, and mixed variant) and two clinical classifications (unicentric [unifocal or localized] and multicentric [multifocal or generalized]). The pathology found with the unicentric presentation is most commonly that of the HV variant. It responds well to surgical resection and is associated with a benign course. The multicentric presentation is rarely composed of lymph nodes with HV pathology, but rather with the plasma cell or mixed pathology. This presentation requires systemic therapy and prognosis is guarded. Associated systemic symptoms are common. There is an increased incidence of CD in patients with HIV. The human herpes virus-8 is associated with nearly all of the HIV-associated CD cases and nearly 50% of non-HIV cases. Interleukin (IL)-6 has also been shown to play a significant role in the pathogenesis of the disease. Paraneoplastic and autoimmune entities are not uncommon in the disorder. Variable benefit has been achieved with single agent chemotherapy, combination chemotherapy, interferon (IFN)-alpha, rituximab, anti-IL-6 receptor antibodies, and thalidomide. Patients with CD are at increased risk for developing frank malignant lymphoma.

show abstract

“…In contrast, its unique effects have been reported such as anti-inflammatory (11), immunomodulatory (12)(13)(14), and antiangiogenic activity (15). Several clinical trials have demonstrated the efficacy of Thal or its analogs in the treatment of a variety of diseases including erythema nodosum leprosum (16), rheumatoid arthritis (17,18), Castleman's disease (19), Crohn's disease (20), and HIV-associated aphthous ulceration (21). In addition, Thal has been used in the treatment of malignancies like AIDS-related Kaposi sarcoma (22), renal cell carcinoma (23), Waldenstrom's macroglobulinemia (24), and myelodysplastic disease (25).…”

mentioning

confidence: 99%

Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice

Tabata

Kadokawa

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

Pulmonary fibrosis in humans can occur as a result of a large number of conditions. In idiopathic pulmonary fibrosis (IPF), pulmonary function becomes progressively compromised resulting in a high mortality rate. Currently there are no proven effective treatments for IPF. We have recently reported that IL-6 and TGF-β1 plays an important role in proliferation and differentiation of lung fibroblasts, and all-trans-retinoic acid (ATRA) prevented bleomycin-induced lung fibrosis through the inhibition of these cytokines. Thalidomide (Thal) has been used in the treatment of multiple myeloma through the inhibitory effect on IL-6-dependent cell growth and angiogenesis. In this study, we examined the preventive effect of Thal on bleomycin-induced pulmonary fibrosis in mice. We performed histological examinations and quantitative measurements of IL-6, TGF-β1, collagen type Iα1 (COL1A1), vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) in bleomycin-treated mouse lung tissues with or without the administration of Thal. Thal histologically ameliorated bleomycin-induced fibrosis in mouse lung tissues. Thal decreased the expressions of IL-6, TGF-β1, VEGF, Ang-1 Ang-2, and COL1A1 mRNA in mouse lung tissues. In addition, Thal inhibited angiogenesis in the lung. In vitro studies disclosed that Thal reduced 1) production of IL-6, TGF-β1, VEGF, Ang-1, and collagen synthesis from human lung fibroblasts, and 2) both IL-6-dependent proliferation and TGF-β1-dependent transdifferentiation of the cells, which could be the mechanism underlying the preventive effect of Thal on pulmonary fibrosis. These data may provide a rationale to explore clinical use of Thal for the prevention of pulmonary fibrosis.

show abstract

Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide

Cited by 47 publications

References 34 publications

Fifty years of multicentric Castleman's disease

Fifty years of multicentric Castleman's disease

Treatment of castleman’s disease

Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice

Contact Info

Product

Resources

About